Examination Report |
1 | Correspondence | 25 Dec 2010 |
10 | Journal Copy | 20 Mar 2018 |
11 | Certificate | 30 May 2018 |
12 | TM-R(RENEWAL OF TRADE MARK) | 11 Mar 2020 |
13 | TM-M(CERTIFICATIE OF REGISTER (U/S 137) / CERTIFIED COPY OF A DOCUMENT) | 20 Nov 2020 |
2 | Additional Representation Sheet | 29 Dec 2010 |
2 | TM-1 | 29 Dec 2010 |
3 | Additional Representation Sheet | 29 Dec 2010 |
3 | TM-1 | 29 Dec 2010 |
4 | MIS-E | 18 Nov 2013 |
5 | TM-16 | 07 Jan 2015 |
6 | Authorization Document (POA) | 07 Jan 2015 |
7 | TM-16 | 20 May 2015 |
8 | Reply to Exam Report (MIS-R) | 04 Sep 2017 |
9 | Hearing Notice | 21 Sep 2017 |
1 | Dispatching of Examination Report for : 2076828 | 1454370 | 888867 | 25 Aug 2014 |
2 | Hearing Notice (Show Cause) | 5034038 | 14 Aug 2017 | |
3 | Hearing Notice (Adjourned) | 5355496 | 08 Nov 2017 | |
4 | RENEWAL INTIMATION LETTER | 9925356 | 15 Mar 2020 |
The application for Ranixime was made on 29 December 2010.
The trademark applicant for Ranixime is SUN PHARMACEUTICAL INDUSTRIES.
Ranixime is applied in class(es) 5.
Application for Ranixime is on Registered stage.
Application Id allotted to Ranixime is 2076828.
Ranixime filed with the Intellectual property office as a WORD.